In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $19.35 in the prior trading day, Sarepta Therapeutics Inc (NASDAQ: SRPT) closed at $20.95, up 8.27%. In other words, the price has increased by $8.27 from its previous closing price. On the day, 3.24 million shares were traded. SRPT stock price reached its highest trading level at $21.21 during the session, while it also had its lowest trading level at $19.35.
Ratios:
Our goal is to gain a better understanding of SRPT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 2.95. In the meantime, Its Debt-to-Equity ratio is 0.95 whereas as Long-Term Debt/Eq ratio is at 0.95.
On September 22, 2025, BMO Capital Markets Upgraded its rating to Outperform which previously was Market Perform but kept the price unchanged to $50.
Oppenheimer Upgraded its Perform to Outperform on July 29, 2025, while the target price for the stock was maintained at $37.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 13 ’25 when Sarepta Therapeutics, Inc. bought 9,265,312 shares for $19.99 per share.
Nicaise Claude sold 2,491 shares of SRPT for $248,203 on Mar 12 ’25. The Director now owns 27,812 shares after completing the transaction at $99.64 per share. On Mar 12 ’25, another insider, Nicaise Claude, who serves as the Director of the company, bought 2,491 shares for $99.65 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SRPT now has a Market Capitalization of 2195291648 and an Enterprise Value of 2604654592. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.91 while its Price-to-Book (P/B) ratio in mrq is 1.66. Its current Enterprise Value per Revenue stands at 1.079 whereas that against EBITDA is -71.785.
Stock Price History:
The Beta on a monthly basis for SRPT is 0.56, which has changed by -0.8428829 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, SRPT has reached a high of $138.81, while it has fallen to a 52-week low of $10.41. The 50-Day Moving Average of the stock is 3.01%, while the 200-Day Moving Average is calculated to be -46.07%.
Shares Statistics:
The stock has traded on average 6.15M shares per day over the past 3-months and 4334010 shares per day over the last 10 days, according to various share statistics. A total of 104.77M shares are outstanding, with a floating share count of 98.75M. Insiders hold about 5.76% of the company’s shares, while institutions hold 85.71% stake in the company. Shares short for SRPT as of 1763078400 were 17999403 with a Short Ratio of 2.93, compared to 1760486400 on 17686193. Therefore, it implies a Short% of Shares Outstanding of 17999403 and a Short% of Float of 19.91.
Earnings Estimates
A detailed examination of Sarepta Therapeutics Inc (SRPT) is currently in progress, with 11.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.73, with high estimates of $1.43 and low estimates of $0.42.
Analysts are recommending an EPS of between $2.3 and -$4.31 for the fiscal current year, implying an average EPS of -$2.01. EPS for the following year is $3.3, with 12.0 analysts recommending between $6.09 and -$2.83.
Revenue Estimates
19 analysts predict $378.32M in revenue for. The current quarter. It ranges from a high estimate of $531.64M to a low estimate of $336.25M. As of. The current estimate, Sarepta Therapeutics Inc’s year-ago sales were $658.41MFor the next quarter, 19 analysts are estimating revenue of $375.7M. There is a high estimate of $433.4M for the next quarter, whereas the lowest estimate is $344.04M.
A total of 20 analysts have provided revenue estimates for SRPT’s current fiscal year. The highest revenue estimate was $2.16B, while the lowest revenue estimate was $2.09B, resulting in an average revenue estimate of $2.12B. In the same quarter a year ago, actual revenue was $1.9BBased on 20 analysts’ estimates, the company’s revenue will be $1.59B in the next fiscal year. The high estimate is $2.24B and the low estimate is $1.31B.
